About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

BMS-986012 in Relapsed/Refractory SCLC | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1/2NCT02247349

BMS-986012 in Relapsed/Refractory SCLC

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in p...

Lead sponsor: Bristol-Myers Squibb•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
•Histological or cytological confirmed small cell lung cancer (SCLC)
•Performance Status 0-1
•Adequate organ function
•Measurable disease

Exclusion Criteria

•Known or suspected brain metastasis
•Small cell cancer not lung in origin
•Significant or acute medical illness
•Uncontrolled or significant cardiac disease
•Infection
•≥ Grade 2 peripheral neuropathy
•Concomitant malignancies
•HIV related disease or known or suspected HIV+
•Hepatitis B or C infection
•ECG abnormalities as defined by the protocol
•Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab

Related studies

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

RECRUITINGPhase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more

RECRUITINGPhase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

NCT07164170 · Non-Small Cell Lung Cancer

RECRUITINGPhase 2

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917 · Non Small Cell Lung Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 5, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment106

Start dateNov 2014

Last updatedMar 5, 2024

Condition

Small Cell Lung Cancer

Locations shown

Local Institution - 0004

New York, New York

Local Institution - 0001

Durham, North Carolina

Local Institution - 0021

Winston-Salem, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions